This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Zeria Pharmaceutical Co., Ltd.

Drug Names(s): Promac (JP)

Description: Z-103 serves as a zinc replacement therapy. Studies in murine models have shown an improvement of the decrease in taste bud proliferation caused by zinc deficiency.

Deal Structure: Zeria and SK Chemicals
In February 2006, SK Chemicals announced that they signed a contract with Zeria for the introduction of PROMAC (polaprezinc) for the treatment of gastritis and gastric ulcers through immuno-modulating and anti-inflammatory actions into the South Korean market.

Partners: SK Chemicals Co., Ltd.

Z-103 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug